<DOC>
	<DOCNO>NCT02499172</DOCNO>
	<brief_summary>This study , carry immediately follow emergency , reactive cholera vaccination campaign Nsanje District , Malawi , cohort study estimate safety kill oral cholera vaccine ( OCV ) , pregnant woman measure ShancholTM , pregnancy outcome birth defect . While limited evidence suggest vaccine safe pregnant woman , set allow investigator answer question community 100,000 people receive vaccine restriction pregnancy status . In past cholera vaccine campaign include clinical trial , pregnant woman exclude due lack safety data . However , campaign , decision Ministry Health benefit offer vaccine individual regardless pregnancy status far outweigh theoretical risk . Here investigator specifically propose : Specific Objective 1 : To conduct surveillance pregnant woman detect adverse pregnancy outcome within community Nsanje District , Malawi receive oral cholera vaccine reactive vaccination campaign start 30 March 2015 . Through household survey enrollment pregnant woman monthly follow-up visit , investigator determine cumulative incidence adverse pregnancy outcome among vaccinated unvaccinated woman Nsanje Chikwawa Districts , Malawi . Specific Objective 2 : To compare cumulative incidence pregnancy loss ( miscarriage stillbirth ) woman receive oral cholera vaccine pregnant woman vaccinate become pregnant end final round vaccination Nsanje Chikwawa Districts , Malawi . Specific Objective 3 : To compare incidence newborn malformation cohort infant fetal exposure oral cholera vaccine compare without exposure Nsanje Chikwawa Districts , Malawi .</brief_summary>
	<brief_title>Follow-up Pregnant Women After Mass Vaccination Oral Cholera Vaccine ( ShancholTM ) Nsanje Malawi</brief_title>
	<detailed_description>Although good reason woman reproductive age participate intervention prevent cholera , cholera vaccination program study generally exclude pregnant woman since little specific information safety vaccine pregnancy . However , several biological reason inactivate OCVs unlikely harmful effect fetal development . First , bacteria vaccine kill replicate . Second , vaccine antigen act locally gastrointestinal mucosa , absorb , enter maternal fetal circulation . Finally , vaccine trigger systemic reaction ( e.g. , fever ) associate miscarriage early pregnancy.According late WHO position paper relation OCV , vaccination country cholera endemic may include group particularly vulnerable severe form cholera , vaccine contraindicate , pregnant woman HIV-infected individual . While WHO recommend vaccination pregnant woman , package insert Dukoral® ShancholTM cautious suggests vaccine recommend use pregnant woman . Even , ShancholTM package insert state , `` Administration ShancholTM pregnant woman may consider careful evaluation benefit risk case medical emergency epidemic '' . In recent result publish 2012 , pregnant woman inadvertently vaccinate Dukoral® mass vaccination campaign Zanzibar 2009 experience harmful effect . On hand , information safety ShancholTM vaccine pregnant woman . New evidence need inform decision true safety vaccine pregnancy . If safe , vaccine valuable tool reduce burden cholera population disproportionately suffer disease . On January 13 , 2015 , President Republic Malawi declare state disaster follow persistent rain result flood affect 15 28 district country . The first confirmed case cholera report Malawi February 11 , 2015 . As 4 March 2015 , Malawi register 72 case 2 death . To stop outbreak cholera , cholera vaccination campaign program carry 30 March 2015 May 3 2015 target camp nearby community Nsanje District . This campaign provide two dos vaccine age eligible people irrespective pregnancy status . This study design follow-up pregnant woman aim follow objective : Specific Objective 1 : To conduct surveillance pregnant woman detect adverse pregnancy outcome within community Nsanje District , Malawi receive oral cholera vaccine reactive vaccination campaign start 30 March 2015 . Through household survey enrollment pregnant woman monthly follow-up visit , investigator determine cumulative incidence adverse pregnancy outcome among vaccinated unvaccinated woman Nsanje Chikwawa Districts , Malawi . Specific Objective 2 : To compare cumulative incidence pregnancy loss ( miscarriage stillbirth ) woman receive oral cholera vaccine pregnant woman vaccinate become pregnant end final round vaccination Nsanje Chikwawa Districts , Malawi . Specific Objective 3 : To compare incidence newborn malformation cohort infant fetal exposure oral cholera vaccine compare without exposure Nsanje Chikwawa Districts , Malawi .</detailed_description>
	<mesh_term>Abortion , Spontaneous</mesh_term>
	<mesh_term>Cholera</mesh_term>
	<mesh_term>Stillbirth</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion : Women age 1549 year old time consent ( cohort ) Urine sample provided pregnancy test require ( Not require : experienced delivery outcome March 30 enrollment date , OR visibly pregnant AND due date indicate Health Passport ) ( cohort ) Received least one dose OCV 2015 ( must verify OCV Vaccination Card ) ( Cohorts 1 &amp; 2 ) Estimated last menstruation least 3 week first dose OCV receive ( Nsanje ) March 30 , 2015 ( Chikwawa ) ( Cohorts 1 &amp; 3 ) Estimated last menstruation least 2 week final dose OCV receive ( Nsanje ) last day OCV Round 2 ( Chikwawa ) ( Cohorts 2 &amp; 4 ) Residing Nsanje Chikwawa Districts since first day vaccination campaign ( 30 March 2015 ) ( Cohorts 2 &amp; 3 ) Provides informed consent ( additional consent parent legal guardian unmarried &lt; 18 year old ) ( All Cohorts ) Exclusion Criteria Received least one dose OCV 2015 ( Cohorts 3 &amp; 4 ) An otherwise eligible pregnant woman unable contacted second attempt within 48 hour first attempt enroll ( All cohort )</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Adverse pregnancy outcome</keyword>
</DOC>